Recursion Pharmaceuticals, Inc. $RXRX Shares Purchased by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. boosted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 89.6% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,339,139 shares of the company’s stock after acquiring an additional 632,900 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Recursion Pharmaceuticals were worth $6,776,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Bank of Montreal Can grew its holdings in shares of Recursion Pharmaceuticals by 35.1% during the second quarter. Bank of Montreal Can now owns 15,718 shares of the company’s stock valued at $80,000 after purchasing an additional 4,081 shares during the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter worth approximately $63,000. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its position in Recursion Pharmaceuticals by 135.3% during the 2nd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 911,085 shares of the company’s stock valued at $4,610,000 after purchasing an additional 523,848 shares during the period. Rossby Financial LCC bought a new position in Recursion Pharmaceuticals during the 2nd quarter worth $142,000. Finally, Teacher Retirement System of Texas grew its stake in Recursion Pharmaceuticals by 18.6% during the 2nd quarter. Teacher Retirement System of Texas now owns 79,567 shares of the company’s stock worth $403,000 after buying an additional 12,452 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, insider Najat Khan sold 36,599 shares of the business’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $5.52, for a total transaction of $202,026.48. Following the sale, the insider directly owned 668,197 shares in the company, valued at approximately $3,688,447.44. The trade was a 5.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 8.43% of the company’s stock.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX opened at $4.62 on Friday. Recursion Pharmaceuticals, Inc. has a 1 year low of $3.79 and a 1 year high of $12.36. The stock has a market cap of $2.01 billion, a price-to-earnings ratio of -2.60 and a beta of 0.93. The business has a fifty day moving average of $5.27 and a 200-day moving average of $5.20. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.58 and a current ratio of 3.58.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.02. The business had revenue of $5.18 million for the quarter, compared to analysts’ expectations of $19.36 million. Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The company’s revenue was down 80.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.34) earnings per share. Equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on RXRX. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Wednesday, October 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday, September 11th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Recursion Pharmaceuticals has an average rating of “Hold” and an average price target of $7.25.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.